Breaking Finance News

Goldman Sachs disclosed Johnson & Johnson (NYSE:JNJ), hiking its price target to $130.00 earlier today

Having a price of $135.22, Johnson & Johnson (NYSE:JNJ) traded -1.49% lower on the day. With the last close up 2.91% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. JNJ has recorded a 50-day average of $132.79 and a two hundred day average of $129.43. Trade Volume was down over the average, with 1,631,248 shares of JNJ changing hands under the typical 5,349,390

Reporting a potential downside of -0.04%, Goldman Sachs upped the price target of Johnson & Johnson (NYSE:JNJ) to $130.00

Recent Performance Chart

Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson has 52 week low of $109.32 and a 52 week high of $137.08 with a PE ratio of 22.54 and has a market capitalization of $0.

In addition to Goldman Sachs reporting its stock price target, a total of 18 brokerages have issued a ratings update on the company. The average stock price target is $117.44 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.